Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Simon Hostettler is a Wissenschaftlicher Assistent at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) since February 2021. Prior to this role, Simon worked as a Postgraduate PU Galenik at Novartis from October 2019 to January 2021 and served as Careanesth at Sitzwachecareanesth between March 2018 and September 2019. Additionally, Simon held the position of Wissenschaftlicher Laborassistent at Universität Bern for a brief period in 2019. Simon obtained a Master's degree in Molecular Life Sciences from Université de Berne in December 2019 and previously earned a Bachelor's degree in Molecular Life Science from the University of Exeter in December 2017.
This person is not in any teams
This person is not in any offices
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of vision, its diseases and to develop new therapies for vision loss. The institute is constituted as a foundation. IOB started operations in 2018. At IOB, we accelerate the conversion of basic research into innovative treatments which change the field of ophthalmic therapy. Interdisciplinary teams of researchers and clinicians work hand in hand. These problem-solvers and innovators have in-depth knowledge of unmet medical needs, and daily exposure to patients. Together, they improve the understanding of vision, and of the cells involved in eye disease. In this highly collaborative environment, IOB turns discoveries and technologies into clinical benefits for patients with blinding conditions. We help advance the practice of ophthalmic disease based on the genetic, structural and functional understanding of the cell types and their interactions within the human eye. At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of eye diseases and to develop new therapies for vision loss.